| Literature DB >> 14988688 |
James Leyden1, Wilma Bergfeld, Lynn Drake, Frank Dunlap, Mitchel P Goldman, Alice B Gottlieb, Michael P Heffernan, Janet G Hickman, Maria Hordinsky, Michael Jarrett, Sewon Kang, Ann Lucky, Gary Peck, Tania Phillips, Marvin Rapaport, Janet Roberts, Ronald Savin, Marty E Sawaya, Alan Shalita, Joel Shavin, James C Shaw, Linda Stein, Daniel Stewart, John Strauss, James Swinehart, Leonard Swinyer, Diane Thiboutot, Ken Washenik, Gerald Weinstein, David Whiting, Frances Pappas, Matilde Sanchez, Lisa Terranella, Joanne Waldstreicher.
Abstract
Excessive sebum production is a central aspect of the pathophysiology of acne vulgaris. Sebaceous gland function is under androgen control and it is hypothesized that dihydrotestosterone is formed by the action of 5 alpha-reductase. Type I is the controlling isoenzyme. This study describes a 3-month, multicenter, randomized, placebo-controlled clinical trial with a potent, selective inhibitor of type I 5 alpha-reductase used alone and in combination with systemic minocycline. Inhibition of type I 5 alpha-reductase was not associated with clinical improvement of acne when used alone and did not enhance the clinical benefit of systemic minocycline. These results indicate the need for further work at the molecular level to better understand the action of androgens on sebaceous gland function.Entities:
Mesh：
Substances：
Year: 2004 PMID： 14988688 DOI： 10.1016/j.jaad.2003.07.021
Source DB: PubMed Journal: J Am Acad Dermatol ISSN： 0190-9622 Impact factor: 11.527